153747-97-8

Basic information

• Product Name: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE
• Synonyms: 4-(5-Bromo-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester;2-(N-Boc-piperazin-1-yl)-5-bromopyridine, tert-Butyl 4-(5μ-bromopyrid-2μ-yl)piperazine-1-carboxylate;5-Bromo-2-[4-(N-Boc)piperazin-1-yl]pyridine;1-Piperazinecarboxylic acid, 4-(5-bromo-2-pyridinyl)-, 1,1-dimethylethyl ester;2-(4-BOC-piperazino)-5-bromopyridine;t-Butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate;Palbociclib impurity C;4-Boc-1-(5-bromo-2-pyridyl)piperazine 97%
• CAS NO: 153747-97-8
• Molecular Formula: C₁₄H₂₀BrN₃O₂
• Molecular Weight: 342.23
• Product Categories: pharmacetical;Organohalides;Pyridine;piperazines;alkyl bromide
• Mol File: 153747-97-8.mol
• Article Data: 19

Chemical Properties

• Melting Point: 83-87 °C(lit.)
• Boiling Point: 433°Cat760mmHg
• Flash Point: 215.6°C
• Appearance: White to yellow/Powder
• Density: 1.372g/cm³
• Vapor Pressure: 1.06E-07mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.06±0.29(Predicted)
• Water Solubility: Soluble in water.
• CAS DataBase Reference: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(153747-97-8)
• EPA Substance Registry System: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(153747-97-8)

Safety Data

• Hazard Codes: T
• Statements: 25-36/37/38
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• Hazardous Substances Data: 153747-97-8(Hazardous Substances Data)

Usage

Uses

4-Boc-1-(5-bromo-2-pyridyl)piperazine is used as active pharmaceutical ingredient.

InChI:InChI=1/C14H20BrN3O2/c1-14(2,3)20-13(19)18-8-6-17(7-9-18)12-5-4-11(15)10-16-12/h4-5,10H,6-9H2,1-3H3

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 624-28-2 2,5-dibromopyridine 
• 149771-44-8 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane 
• 766-11-0 5-bromo-2-fluoropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 

Downstream Products

• 1188335-25-2 tert-butyl 4-[5-(4-{(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-2-pyridinyl]-1-piperazinecarboxylate 
• 496786-98-2 2-(4-tert-butyloxycarbonyl-piperizin-1-yl)pyridine-5-boronic acid pinacol ester 
• 683274-61-5 tert-butyl 4-(5-cyanopyridine-2-yl)piperazine-1-carboxylate 
• 1188918-41-3 N-({(5S)-3-[3-fluoro-4-(6-{4-[(2-methyl-6-nitro-2,3-dihydro-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]-1-piperazinyl}-3-pyridinyl)-phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide 
• 380381-49-7 N-[((5S)-3-{3-fluoro-4-[6-(1-piperazinyl)-3-pyridinyl]-phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 
• 919347-67-4 (6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-3-yl)boronic acid 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 

Relevant articles and documents

Selective Amination of Polyhalopyridines Catalyzed by a Palladium-Xantphos Complex

(Matrix presented) Amination of 5-bromo-2-chloropyridine (1a) catalyzed by a palladium-Xantphos complex predominately gives 5-amino-2-chloropyridine product 3a in 96% isolated yield and excellent chemoselectivity (3a/4a = 97:3). Amination of 2,5-dibromopyridine (11) under the same conditions exclusively affords 2-amino-5-bromopyridine 4a.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

3-substituent-5-(substituted aryl)-7-azaindole derivative and application thereof

The invention discloses a 3-substituent-5-(substituted aryl)-7-azaindole derivative and application thereof. The structural formula of the 3-substituent-5-(substituted aryl)-7-azaindole derivative is shown in the specification, and the 3-substituent-5-(substituted aryl)-7-azaindole derivative has obvious anti-coronavirus activity. In-vitro binding experiments show that the 3-substituent-5-(substituted aryl)-7-azaindole derivative disclosed by the invention generally has relatively strong affinity with a drug target 3CLPro protease of coronavirus, can effectively inhibit the activity of the 3CLPro protease, and is a small molecular ligand for targeted inhibition of 3CLPro.